TGTX - TG THERAPEUTICS, INC.
IEX Last Trade
33.34
0.190 0.570%
Share volume: 25,881
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$33.15
0.19
0.57%
Fundamental analysis
22%
Profitability
19%
Dept financing
15%
Liquidity
69%
Performance
15%
Performance
5 Days
-0.31%
1 Month
-6.13%
3 Months
37.85%
6 Months
81.39%
1 Year
89.29%
2 Year
296.06%
Key data
Stock price
$33.34
DAY RANGE
$31.73 - $33.40
52 WEEK RANGE
$13.28 - $36.84
52 WEEK CHANGE
$82.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Michael S. Weiss
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
Recent news